← Leaderboards
Luis A Diaz
Johns Hopkins University
$3,009,445
Attributed
$4,772,489
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $725.2K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,772,489 · 2
By mechanism
R01$4,772,489 · 2
Top collaborators
- Lee W Jones6 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Michael A Jacobs$5,618,894
- Shibin Zhou$2,815,529
- Christine A Iacobuzio-Donahue$15,673,191
- Ian W Flinn$2,994,223
- Kristine Glunde$12,806,818
Others in their field
Top investigators on “Laboratories”
- David Heimbrook · Leidos Biomedical Research, Inc.$943,075,715
- Lawrence Corey · Fred Hutchinson Cancer Center$747,603,944
- Jeffrey P Krischer · University Of South Florida$627,303,958
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$553,634,937
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$463,311,620
Research focus
LaboratoriesFuturePre-ClinicalToxic EffectCancer PatientDoseInflammatoryMalignant NeoplasmsSolid NeoplasmTumorSafetyProgramsBaseAdherenceAppropriate DoseCohortAntitumor EffectClinicClinical InvestigationColorectal CancerCellsCell SurvivalAdjuvant TherapyBiological
Grant awards (10)
Exercise as Interception Therapy in Primary High Risk Cancer$693,662
R01 · FY2025 · CA
Exercise as Interception Therapy in Primary High Risk Cancer$624,661
R01 · FY2024 · CA
Exercise as Interception Therapy in Primary High Risk Cancer$644,390
R01 · FY2023 · CA
Exercise as Interception Therapy in Primary High Risk Cancer$644,389
R01 · FY2022 · CA
Exercise as Interception Therapy in Primary High Risk Cancer$193,799
R01 · FY2021 · CA
Exercise as Interception Therapy in Primary High Risk Cancer$725,188
R01 · FY2020 · CA
Phase I study of Clostridium novyi-NT spores in solid tumor cancer patients$311,600
R01 · FY2010 · CA · contact PI
Phase I study of Clostridium novyi-NT spores in solid tumor cancer patients$311,600
R01 · FY2009 · CA · contact PI
Phase I study of Clostridium novyi-NT spores in solid tumor cancer patients$311,600
R01 · FY2008 · CA · contact PI
Phase I study of Clostridium novyi-NT spores in solid tumor cancer patients$311,600
R01 · FY2007 · CA · contact PI